MNPR vs. AGE, ERNA, GRTX, GHSI, PPBT, MBRX, IMNN, ELAB, ATHE, and RDHL
Should you be buying Monopar Therapeutics stock or one of its competitors? The main competitors of Monopar Therapeutics include AgeX Therapeutics (AGE), Eterna Therapeutics (ERNA), Galera Therapeutics (GRTX), Guardion Health Sciences (GHSI), Purple Biotech (PPBT), Moleculin Biotech (MBRX), Imunon (IMNN), Elevai Labs (ELAB), Alterity Therapeutics (ATHE), and RedHill Biopharma (RDHL). These companies are all part of the "pharmaceutical preparations" industry.
Monopar Therapeutics (NASDAQ:MNPR) and AgeX Therapeutics (NYSE:AGE) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings, valuation and community ranking.
1.8% of Monopar Therapeutics shares are owned by institutional investors. Comparatively, 12.5% of AgeX Therapeutics shares are owned by institutional investors. 41.6% of Monopar Therapeutics shares are owned by insiders. Comparatively, 6.5% of AgeX Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Monopar Therapeutics has higher earnings, but lower revenue than AgeX Therapeutics. Monopar Therapeutics is trading at a lower price-to-earnings ratio than AgeX Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, AgeX Therapeutics had 1 more articles in the media than Monopar Therapeutics. MarketBeat recorded 1 mentions for AgeX Therapeutics and 0 mentions for Monopar Therapeutics. Monopar Therapeutics' average media sentiment score of 0.00 equaled AgeX Therapeutics'average media sentiment score.
Monopar Therapeutics has a beta of 1.19, meaning that its share price is 19% more volatile than the S&P 500. Comparatively, AgeX Therapeutics has a beta of 1.18, meaning that its share price is 18% more volatile than the S&P 500.
AgeX Therapeutics received 11 more outperform votes than Monopar Therapeutics when rated by MarketBeat users. However, 70.37% of users gave Monopar Therapeutics an outperform vote while only 64.47% of users gave AgeX Therapeutics an outperform vote.
Monopar Therapeutics has a net margin of 0.00% compared to AgeX Therapeutics' net margin of -10,424.65%. AgeX Therapeutics' return on equity of 0.00% beat Monopar Therapeutics' return on equity.
Monopar Therapeutics presently has a consensus price target of $2.00, indicating a potential upside of 210.08%.
Summary
Monopar Therapeutics beats AgeX Therapeutics on 8 of the 14 factors compared between the two stocks.
Get Monopar Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for MNPR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MNPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Monopar Therapeutics Competitors List
Related Companies and Tools
